Nvidia vs. Micron: The AI Revolution Is Big Enough for Both. Here's the Better Buy.
2026-10-25 08:30
•Adria Cimino •The Motley Fool
••••• •• Axe Cap view
Nvidia or Micron: Which AI Play Wins?
Nvidia’s broad AI dominance beats Micron’s cyclical memory bets for South African investors.
Nvidia leads the AI chip space with a diverse product line that goes beyond GPUs into software and data centers. Its earnings growth has been stunning, and its AI business doesn’t rely heavily on cyclical demand swings. Micron, on the other hand, is tied to memory prices, which have a history of booms and busts. Although Micron has locked in solid multi-year contracts thanks to the AI hype, oversupply risks loom large. For South Africans watching from the JSE, Nvidia’s story is also easier to understand because it hints at longer-term stability. The rand’s trajectory against the dollar (USD/ZAR) remains a big factor since Nvidia’s shares trade overseas, and rand weakness could make dollar-exposed tech stocks pricier locally. Still, if memory prices resist falling, Micron could surprise. That’s a risk tech investors must weigh carefully. this is just our opinion and not financial advice
Buy Nvidia via USD/ZAR exposure as a core AI growth play but keep Micron on watch for entry points if memory prices stabilize.
- USD/ZAR
- NVDA
- Memory price normalization hitting Micron revenue
- Rand weakening inflating USD tech stock costs locally
6/10
Both Nvidia and Micron are key players in the AI revolution, with Nvidia dominating AI chip manufacturing and Micron providing essential memory and storage solutions. While both stocks have delivered exceptional returns over five years, the article recommends Nvidia as the better buy due to its diversified AI portfolio and non-cyclical market position, whereas Micron faces vulnerability to memory price declines once supply normalizes.
Our take is based on reporting first published by The Motley Fool.
More stories like this
- Elon Musk Wants to Give Every American Child a Share of SpaceX. Here's What It Would Cost -- and What It Means for Everyone Else Holding the Stock
- Amgen vs. Gilead Sciences: Which Biotech Dividend Stock Is the Better Buy?
- Prediction: This Is Where Palantir Stock Will Trade When Its Revenue Hits $10 Billion